A new treatment for B-cell acute lymphoblastic leukemia using an antibody-drug conjugate
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
This study is testing a new treatment that uses a special drug to help kids and young adults with B-cell acute lymphoblastic leukemia (B-ALL) by targeting cancer cells while trying to keep healthy cells safe, so patients can have a better chance of recovery with fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hospitals and Clinics NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10884330 on NIH RePORTER |
What this research studies
This research investigates a novel antibody-drug conjugate targeting the pre-B-cell receptor to treat B-cell acute lymphoblastic leukemia (B-ALL), a common cancer in children and young adults. The approach aims to improve treatment outcomes by addressing the challenges of relapse and complications from current therapies, which often lead to severe immune dysregulation. By focusing on specific B-cell surface markers, the treatment seeks to minimize damage to normal B cells while effectively targeting cancerous cells. Patients may benefit from a safer and more effective treatment option that reduces the risk of infections and other serious side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults diagnosed with B-cell acute lymphoblastic leukemia, particularly those who have experienced relapses.
Not a fit: Patients with other types of leukemia or those who do not have B-cell acute lymphoblastic leukemia may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with B-cell acute lymphoblastic leukemia.
How similar studies have performed: Other research has shown promise in using antibody-drug conjugates for treating various cancers, indicating potential success for this novel approach.
Where this research is happening
Minneapolis, United States
- Children's Hospitals and Clinics — Minneapolis, United States (Active)
Researchers
- Principal investigator: Winter, Stuart Sheldon — Children's Hospitals and Clinics
- Study coordinator: Winter, Stuart Sheldon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.